Diaceutics (LON:DXRX) Sets New 12-Month High - Here's What Happened

Key Points

• Diaceutics PLC's shares reached a new 52-week high at GBX 165 ($2.20), with the last trading price at GBX 162.74 ($2.17) after 324,604 shares changed hands.
• Brokerages have set new price targets for Diaceutics, with Canaccord Genuity maintaining a "buy" rating and establishing a target of GBX 180, while Royal Bank of Canada adjusted theirs down to GBX 185.
• The stock currently holds a consensus rating of "Buy" and an average price target of GBX 175 from various analysts.

Diaceutics PLC (LON:DXRX - Get Free Report) shares hit a new 52-week high on Thursday . The company traded as high as GBX 165 ($2.20) and last traded at GBX 162.74 ($2.17), with a volume of 324604 shares trading hands. The stock had previously closed at GBX 160 ($2.14).

Analysts Set New Price Targets

A number of brokerages have weighed in on DXRX. Canaccord Genuity Group reiterated a "buy" rating and issued a GBX 180 price target on shares of Diaceutics in a report on Tuesday, July 22nd. Royal Bank Of Canada decreased their price target on shares of Diaceutics from GBX 195 to GBX 185 and set an "outperform" rating on the stock in a report on Thursday, July 10th. Three research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of GBX 175.

Diaceutics Price Performance

The stock has a market cap of £137.60 million, a PE ratio of -8,056.63 and a beta of 0.58. The company has a current ratio of 4.85, a quick ratio of 9.92 and a debt-to-equity ratio of 0.39. The company's 50 day moving average is GBX 138.95 and its 200-day moving average is GBX 128.18.

Diaceutics (LON:DXRX - Get Free Report) last released its quarterly earnings results on Tuesday, September 23rd. The company reported GBX (2.84) earnings per share (EPS) for the quarter. Diaceutics had a negative return on equity of 7.15% and a negative net margin of 10.90%. As a group, sell-side analysts predict that Diaceutics PLC will post 1.0107919 earnings per share for the current year.

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.